# Phase II Study of RAD001 Head and Neck Cancer

> **NCT01051791** · PHASE2 · TERMINATED · sponsor: **Julie E. Bauman, MD, MPH** · enrollment: 13 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **DRUG:** Everolimus 10mg daily

## Key facts

- **NCT ID:** NCT01051791
- **Lead sponsor:** Julie E. Bauman, MD, MPH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-01
- **Primary completion:** 2011-04-26
- **Final completion:** 2016-08-05
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2017-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01051791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01051791, "Phase II Study of RAD001 Head and Neck Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01051791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*